Recurrent Ovarian Carcinoma Recruiting Phase 1 Trials for Ipilimumab (DB06186)

IndicationStatusPhase
DBCOND0030000 (Recurrent Ovarian Carcinoma)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03508570Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal CarcinomatosisTreatment